Daily Archives: February 27, 2020

New topical treatments for psoriasis increasingly prove that vehicles matter, says an expert who spoke at the South Beach Symposium. Additional noteworthy developments include new fixed combinations and new molecules under development.

RELATED:IL-23 inhibitors may offer psoriasis patients longer-lasting results

The polyaphron dispersion (PAD) vehicle platform (MC2 Biotek) includes 10 to 30 times less surfactants than other emulsions, which makes it less irritating, says Leon Kircik, M.D. He is clinical professor of dermatology, Icahn School of Medicine at Mount Sinai, New York; associate clinical professor of dermatology, Indiana University Medical Center; and Medical Director, Physicians Skin Care, PLLC, and Skin Sciences, PLLC, in Louisville, KY.

PAD technology also uses a robust lipid shell that allows high stability in aqueous environments.

"So now you have a less irritating, more durable vehicle," he adds.

In phase 3, the combination of calcipotriene and betamethasone diproprionate in the PAD vehicle (Enstilar foam, LEO Pharma) proved superior to a calcipotriene-betamethasone topical suspension ointment (Taclonex, LEO Pharma). The proportions of patients who were clear or nearly clear with at least a two-point improvement over baseline were 40% for the foam versus 22% for ointment.

Disclosures:

Dr. Kircik has served as an investigator, speaker, advisor or consultant for Amgen, Celgene, Clarify, Dermavant, LEO and MC2 Biotek.

References:

Leon Kircik, M.D. "Topical Therapies for Psoriasis," South Beach Symposium. February 8, 2020.

View original post here:
Psoriasis: An update on topical therapies - Dermatology Times

Last year, shares of the big pharma company Johnson & Johnson(NYSE:JNJ) rose by 13%, a performance that trailed that of the pharmaceuticals industry, which was up by 24.7% as measured by the SPDR S&P Pharmaceuticals Index. The S&P 500 -- which was up by about 29% in 2019 -- also outpaced Johnson & Johnson last year.

There are several reasons why Johnson & Johnson did not perform as well as the broader market in 2019. First, some of its key products within its pharmaceuticals segment -- by far its largest segment by revenue -- have been recording declining sales. For instance, the company's rheumatoid arthritis drug Remicade reported $4.4 billion in sales for the full fiscal year 2019, down 17.8% year over year.Second, Johnson & Johnson is currently drowning in a sea of lawsuits. A California court recently ordered Johnson & Johnson to pay $344 million for "deceptively marketing" its pelvic mesh products, which are surgical implants aimed at treating pelvic organ prolapse.Johnson & Jonhson plans to appeal this decision, but there are more lawsuits the company has to worry about.

Amid all these troubles, investors might be inclined to avoid shares of the pharma giant altogether. However, a lot can happen in just one year, and despite its issues, Johnson & Johnson's trajectory within the next 12 months may not be that catastrophic. Here's why.

Image source: Getty Images.

While some of Johnson & Johnson's pharmaceutical products are losing steam, others are on the rise. The company's drug Stelara, which treats plaque psoriasis and psoriatic arthritis, recorded $6.4 billion in sales during fiscal year 2019, a 23.4% year-over-year increase. Tremfya, which is a treatment for severe plaque psoriasis, reported $1 billion in sales, up 85.9% compared with the previous fiscal year. Further, Johnson & Johnson's cancer drug Imbruvica recorded $3.4 billion in sales, up 30.4% year over year, and Darzalex -- which treats multiple myeloma-- recorded about $3 billion in sales, 48% higher than in fiscal year 2018.

In other words, Johnson & Johnson has enough products with sales on the rise -- and will likely continue delivering growing sales -- to keep revenue from its pharmaceuticals segment afloat. Some of the company's current products are also seeking additional indications.For instance, Imbruvica is currently in phase 3 testing for the treatment of mantle cell lymphoma, and Tremfya is in phase 3 testing for the treatment of pediatric psoriasis.

Also, Johnson & Johnson recently submitted a supplemental Biologics License Application to the U.S. Food and Drug Administration for Darzalex as a treatment for relapsed/refractory multiple myeloma (that is, multiple myeloma that does not respond to treatment or resurfaces after a period of remission). According to estimates, about 32,270 people will be diagnosed with relapsed/refractory multiple myeloma in 2020, and approximately 12,830 will die from it. Lastly, with the novel coronavirus outbreak worsening by the day, Johnson & Johnson is partnering with the U.S. Department of Health and Human Services to develop a vaccine for COVID-19, the deadly disease caused by the virus.

While Johnson & Johson boast a strong product lineup, the company has to contend with some competitors in these markets. For instance, AbbVie's (NYSE:ABBV) Humira is a treatment for plaque psoriasis. And although Humira is experiencing declining sales due to generic competition in Europe, it remains a blockbuster drug. Humira recorded $19.2 billion in sales in 2019.AbbVie's Skyrizi -- which also treats plaque psoriasis -- has been recording growing sales. Skyrizi was approved by the FDA for moderate to severe plaque psoriasis in April 2019, and the drug generated $355 million in sales last year.

Novartis (NYSE:NVS) is another pharma company with footprints in this market. The company's top-selling product Cosentyx, which treats moderate to severe plaque psoriasis -- generated $3.6 billion in sales last year.

In the market for multiple myeloma, Johnson & Johnson competes with Bristol-Myers Squibb (NYSE:BMY). Thanks to its acquisition of Celgene in a cash and stock transaction valued at $74 billion, Bristol-Myers acquired such products as Revlimid. Sales of Revlimid -- from the time of the closing of the acquisition on Nov. 20, to the end Bristol-Myers' third quarter, on Dec. 31 -- were $1.3 billion.Bristol-Myers should also submit ide-cel -- a potential treatment for relapsed/refractory multiple myeloma -- to the FDA sometime this year for approval.

Also,it isn't clear whether the company will benefit from its current efforts to develop a vaccine for COVID-19. While the epidemic continues to get worse -- with cases outside of China and in countries such as Italy and Iran growing --several companies are currently working on that project, and some of Johnson & Jonhson's peers could beat the company to the punch.

Even given these competitors, Johnson & Johnson's pipeline, as well as its current lineup should allow the company's sales to remain afloat.

One of Johnson & Johnson's biggest attractions is its dividend history. The company -- which ranks as one of the prestigious dividend aristocrats -- has more than 50 years of consecutive dividend increases under its belt,and Johnson & Johnson still affirms the importance of rewarding shareholders by way of dividend increases.

Chief Financial Officer Joseph J. Wolk said:

As investors in Johnson & Johnson know, delivering a competitive and increasing dividend is a capital allocation priority for us. In 2019, we returned almost $10 billion to investors, which is approximately 50% of our free cash flow, increasing the quarterly dividend by 5.6%.

The company's current dividend yield is 2.56%, and its payout ratio is 66.6%.Investors can count on Johnson & Johnson to keep increasing its quarterly dividend payout within the next year.

What should investors make of Johnson & Johnson's current legal troubles? On the one hand, the company has faced scores of lawsuits before. The pharma giant has always managed to come out of these relatively unscathed. The recent verdict mentioned above cost Johnson & Johnson $344 million. For context, this merely represents about 1.7% of the company's net sales during the fourth quarter.

On the other hand, these ongoing (and numerous lawsuits) represents a risk for Johnson & Jonhson. The company itself mentions risks, including "declining sales and reputational damage," that could ensue as a result of these lawsuits. Johnson & Jonhson continually monitors these legal troubles and the company records provisions for losses for those lawsuits for"which a loss is probable or reasonably possible."Investors should keep a close eye on the lawsuits that are currently plaguing Johnson & Johnson.

Johnson & Johnson didn't outperform the S&P 500 last year, and it is unlikely to do so this year. Also, there are other pharma giants that are likely to outperform the company over the next year. For instance, Bristol-Myers is still riding the wave from its Celgene acquisition and the company performed well during the fourth quarter. Further, Bristol-Myers currently provides better value. The company is trading at 8.44 times future earnings and its price to earnings growth (PEG) is 0.76. By contrast, Johnson & Johnson forward P/E is 14.9 while its PEG is 2.93. While I think both of these companies deserve consideration, I believe Bristol-Myers is a better pick given the 12 months time horizon.

Read this article:
Where Will Johnson & Johnson Be in 1 Year? - Motley Fool

's () Stuart Ashman caught up with Proactive London's Andrew Scott following the news they've agreed a deal with Dutch firm Winclove Probiotics to develop a food supplement to combat psoriasis.

The pair plan to carry out a human study on mild to moderate sufferers of the skin condition, which will take between 12 and 18 months ahead of commercialisation and launch of the probiotic.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of SkinBioTherapeutics PLC named herein, including the promotion by the Company of SkinBioTherapeutics PLC in any Content on the Site, the Company...

Go here to see the original:
SkinBioTherapeutics teams up with Winclove Probiotics for psoriasis supplement - Proactive Investors UK

(This story was first published in the Times of India on February 21, 2020)

CLAIM

A loose translation of the Hindi text describing the video goes -- Siddha Yogi who took samadhi 300 years ago in Chennais Velayur Temple. The saint was found alive during the recent excavation works at the temple."

A reader sent the video along with this claim to Times Fact Check on our WhatsApp number 8527001433 to know if such an incident happened.

whatsapp query.

VERIFICATION AND METHODOLOGY

After breaking the video into different key frames using InVid Google Chrome extension, we ran reverse-image searches on them. This led us to a news report from Daily Mail UK, dated June 29, 2019.

Titled Bear man's identity is revealed: Doctor says emaciated 'living mummy' who appeared in shocking footage is really his patient suffering chronic psoriasis and was never mauled by beast, the report mentioned that the man in the video was actually a 41-year-old patient at Aktobe Medical Centre in Kazakhstan receiving treatment for severe psoriasis.

A senior medic from the hospital where hes admitted rubbished these claims and insisted that the 41-year-old man was never attacked by a wild beast and said he suffered from chronic psoriasis and other medical complications.

More:
Fake News Alert: Video of Kazakhstan man shared as of Indian saint who took 'samadhi' 300 years ago - Pune Mirror

The Psoriasis Drugs Market research report 2019 includes analysis of factual data that provides research results, vital recommendations, conclusions, and other important information to the readers, who in turn bases clients decision making on the content of the report. Psoriasis Drugs Market research report also highlights each of the prominent factors related to the growth of the market are: growing GDP, revenue, demographics, increasing purchasing power, increasing demand, government incentives, government policies, regulatory policies, product standards, and manufacturing standards(as per applicable).

The Global Psoriasis Drugs market size was valued at USD 11.3 billion in 2016. It is anticipated to post a CAGR of 9.4% during the forecast period.

Click Here to Get Sample Of The Report:

https://www.marketinsightsreports.com/reports/03191152581/global-psoriasis-drugs-market-research-report-2019/inquiry?mode=82.

Psoriasis is a genetic condition that may not be present at birth. The condition may be triggered by certain environmental and genetic factors. Changing lifestyles of people are leading to increased alcohol consumption and smoking, unhealthy diet, and sedentary living, which makes people more prone to this condition.

The major manufacturers covered in this report:

AbbVie, Amgen, Johnson & Johnson, Novartis, Eli Lilly, AstraZeneca, Celgene

Psoriasis Drugs Market Product Type:

TNF-inhibitors

Interleukin-inhibitors

Others

Psoriasis Drugs Market Applications:

Hospital

Clinic

Psoriasis DrugsAvail Upto 20% Discount On This Report At:

https://www.marketinsightsreports.com/reports/03191152581/global-psoriasis-drugs-market-research-report-2019/discount?mode=82.

Geographical Regional Analysis of The Report Including Several Regions:

Geographical markets are covered separately within thePsoriasis Drugsreport that includes a competitive analysis on their market performance in the base year as well as predictions for the forecast year. Regions covered in the report such asNorth America(United States, Canada and Mexico),Europe industry(Germany, France, UK, Russia and Italy), Asia-Pacific(Southeast Asia, China, Korea, India and Japan), South America industry(Brazil, Argentina, Colombia),Middle East and Africa(Saudi Arabia, UAE, Egypt, Nigeria and South Africa), South East Asia, Japan, China,andIndiaare also predictable to witness vigorous growth in their respective markets for GlobalPsoriasis DrugsMarket in the near future, states the research report. It focuses on the leading and the progressing countries from every region in detail.

Market Report has been studied and presents an actionable idea to key contributors working in it. The report integrates several drivers as well as factors that impede the growth of this market during the forecast to 2019-2025. An extensive qualitative analysis of factors responsible for driving the market growth and future opportunities has been provided in the market overview section.

Important Features that are under Offering and Key Highlights of the Reports:

Detailed overview ofPsoriasis DrugsMarket Changing market dynamics of the industry In-depth market segmentation by Type, Application etc. Historical, current and projected market size in terms of volume and value Recent industry trends and developments Competitive landscape ofPsoriasis DrugsMarket Strategies of key players and product offerings Potential and niche segments/regions exhibiting promising growth

The market research reports also include detailed information about the major players. The information provides gross profit, revenue, business distribution, the share of the market, and etc. Along with the major players, the development of the market in the focused region is also tailored in the report.

Browse Full Report at:

https://www.marketinsightsreports.com/reports/03191152581/global-psoriasis-drugs-market-research-report-2019?mode=82.

A thorough study of the competitive landscape of the GlobalPsoriasis DrugsMarket has been given, presenting insights into the company profiles, financial status, recent developments, mergers and acquisitions, and the SWOT analysis. This research report will give a clear idea to readers about the overall market scenario to further decide on this market project.

We also offer customization on reports based on specific client requirement:

1- Country level analysis for any 5 countries of your choice.

2- Competitive analysis of any 5 key market players.

3- 40 analyst hours to cover any other data points

Contact Us:

Irfan Tamboli (Head of Sales) Market Insights ReportsPhone: + 1704 266 3234 | +91-750-707-8687[emailprotected]|[emailprotected]

Go here to see the original:
Psoriasis Drugs Market Competitive Insights And Precise Outlook 2018 to 2025 - Galus Australis